HOME >> BIOLOGY >> NEWS
Brain areas identified that 'decode' emotions of others

(Kingston, ON) Queen's psychologists have discovered that our ability to assess how other people are feeling relies on two specific areas of the brain.

The findings, published in the April issue of the Journal of Cognitive Neuroscience, are expected to have implications for the treatment of developmental disorders such as autism.

Led by Mark Sabbagh, the study is supported by a grant from the Natural Sciences and Engineering Research Council (NSERC). Also on the team, from the Queen's Psychology Department, are Margaret Moulson and Kate Harkness.

The study helps us understand the neural bases of everyday "theory of mind": our ability to explain behaviour in terms of mental states like intentions and desires. "What we're showing is that an important first step [in theory of mind] is being able to decode other people's mental states, and that this skill is carried out within a very specific neural pathway,"says Dr. Sabbagh.

The researchers used a technique called event-related potential.This involves fitting people with what looks like a hairnet containing 128 sponge electrodes that attach to their scalps and record electroencephalogram (EEG) signals. Images of eyes conveying different emotions (e.g. anger, sadness, embarrassment) are shown to the subjects, who are then asked to identify both the mental state and gender of the person in each picture, based solely on seeing that person's eyes.

By comparing the EEG signals associated with each response, the researchers identified two precise areas in the brain that were specifically activated when the participants made judgments about mental states: the medial temporal region and the orbital frontal cortex.

These "neural correlates" are already known to be associated with viewing emotional stimuli, such as a frightened face. Until now, however, there has been no evidence that their activation can be intentionally controlled.

"Our study shows that, not only will
'"/>

Contact: Nancy Dorrance
dorrance@post.queensuc.a
613-533-2869
Queen's University
15-Apr-2004


Page: 1 2

Related biology news :

1. Brain has center for detecting sound motion
2. Brains reward circuitry revealed in procrastinating primates
3. Brain serotonin enzyme finding might explain psychiatric disorders
4. Brain development and puberty may be key factors in learning disorders
5. Organization for Human Brain Mapping 2004 Annual Meeting
6. Brain disease research, particle physics meet in the middle (ware)
7. Brain control
8. Brain cells become more discriminating when they work together
9. Brain signal predicts working memory prowess
10. Brain Centre gives Wales a world lead
11. AAAS hosts Battle of the Brains to choose area student for international competition

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Brain areas identified that decode emotions others

(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: